Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Matt Hancock

- PMLiVE

COVID-19 vaccine protection wanes over time, backing up the need for boosters

While both Pfizer/BioNTech and AstraZeneca’s vaccines offer good protection, a new UK study shows the protection reduces over time and the UK's booster campaign is likely to begin in September

- PMLiVE

US health leaders greenlight COVID-19 booster shots for “all Americans”

In light of “very clear” evidence that protection from COVID-19 vaccines declines over time, the US will start offering boosters shots from September

- PMLiVE

US health leaders greenlight COVID-19 booster shots for “all Americans”

In light of “very clear” evidence that protection from COVID-19 vaccines declines over time, the US will start offering boosters shots from September

- PMLiVE

WHO to test three more potential COVID-19 treatments

The expanded Solidarity PLUS trial will test artesunate, imatinib and infliximab on hospitalised COVID-19 patients in a trial that will involve thousands of researchers in 52 countries

- PMLiVE

Pfizer/BioNTech submit data for COVID-19 booster shots

Booster shots are expected to be approved quickly in the US, as cases of delta variant surge

- PMLiVE

First oral antiviral drug for COVID-19 reviewed by Health Canada

Early phase 2/3 data including early safety, quality and efficacy data for Merck’s molnupiravir will be reviewed by the regulator while the study is still underway

- PMLiVE

CureVac to push ahead with first- and second-generation COVID-19 vaccines

The biotech will seek EMA approval for first-generation jab while trials are due to start for second-generation jabs in Q4

- PMLiVE

EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19

FDA approval has already been granted following positive phase 3 trials

- PMLiVE

Valneva’s COVID-19 vaccine to be tested in older people

The trial for VLA2001 will involve people over the age of 56 in New Zealand and aims to generate additional safety and immunogenicity data in older people

- PMLiVE

South Korean company SK bioscience moves into phase 3 trials for its COVID-19 vaccine

Part of the Wave 2 vaccine programme, GBP510 will bolster South Korea’s domestic supply if successful

- PMLiVE

BioNTech to use COVID vaccine profits to “expand and accelerate” pipeline

Vaccine maker posts first-half profits of €3.9bn compared to a loss of €142m a year earlier as demand for the innovative mRNA jab remains strong

- PMLiVE

Moderna deal to build state-of-the-art manufacturing plant bolsters Canada’s vaccine production

The new manufacturing facility will enhance the country’s “rapid pandemic response capabilities”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links